2021 Revenues ($USD) : $4,530,743,855
2021 Revenues (foreign currencies) : ₹334,981,000,000
2021 R&D spend : $290,782,051
2021 Number of Employees : 18,193
Fiscal Year End : 3/31/2021
Leader : Managing director Dilip Shanghvi

Sun Pharma is the fourth largest specialty generic pharmaceutical company. Its 2014 acquisition of Ranbaxy made Sun Pharma the biggest pharma company in India. The acquisition also gave the company a legal headache in the U.S. that led the company to settle in the U.S. District Court for the District of Massachusetts for $485 million. One sales highlight in 2021 is the psoriasis treatment Ilumya (tildrakizumab-asmn), whose sales were $143 million, an increase of 51% over the prior year. In 2021, the company launched Ilumya (tildrakizumab injection) for moderate-to-severe plaque psoriasis in Canada. In the U.S., it launched an acne product known as Winlevi (clascoterone) cream 1%. With more than 40 manufacturing facilities, the company serves patients in more than 100 countries worldwide. —BB